On 2 February 2026, Sandoz announced that it has launched Enzeevu®, biosimilar to Regeneron/Bayer’s Eylea® (aflibercept) 2mg, in Canada. Enzeevu® was approved by Health Canada in October 2025 for all Eylea® indications.
Other aflibercept biosimilars approved in Canada include Biocon’s Yesafili® (June 2025, launched July 2025 following a settlement with Regeneron/Bayer), Amgen’s Pavblu® (July 2025), Apotex’s Aflivu™ (July 2025), Samsung Bioepis’ Opuviz® (October 2025), Celltrion’s Eydenzelt® (November 2025), and Formycon/Klinge/Valorum Biologics’ Ahzantive™ (November 2025).